Eugastro GmbH

Leipzig 42 trials 18 recruiting

42 Registered trials

18 Currently recruiting

Organisation

Eugastro GmbH

Location

Leipzig, Germany

Identifier

ORG-100044276

Address

Johannisplatz 1, Zentrum Sudost, 04103, Germany

Departments

-
DE10027: Gastroenterologie
EUGASTRO GmbH
Gastroenterologie und Hepatologie am Johannisplatz
Gastroenterology
Gastroenterology and Hepatology
Internal Medicine, Gastroenterology, Hepatology
Internistische Praxis
N/A
NA
not applicable
Zentrum Sudost

Clinical trials at this site (42)

Search interface

A Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis Ended

2024-510627-20-00 Non-alcoholic Steatohepatitis (NASH) Cirrhosis 5 2023-07-28
Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Crohn's Disease Ended

2023-504741-32-00 Moderately to Severely Active Crohn's Disease 4 2022-11-30
Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colit… Ended

2023-504743-13-00 Moderately to Severely Active Ulcerative Colitis 4 2022-11-30
A clinical study to assess the efficacy and safety of lanifibranor followed by an active treatment extension in adult patients with non-cirr… Ended

2023-508248-23-00 Non-alcoholic steatohepatitis (NASH) 5 2021-11-26
Research study on whether semaglutide works in people with non-alcoholic steatohepatitis (NASH) Ended

2023-506962-30-00 Non-alcoholic steatohepatitis (NASH) 5 2021-03-29
A Double-blind Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80… Ended

2024-512232-30-00 Primary Biliary Cholangitis 10 2021-01-18
A Study to compare the efficacy of Risankizumab and Utsekinumab in Subjects with Moderately to Severe Active Crohns Disease Ended

2022-501645-70-00 Crohns Disease 5 2020-11-25
A clinical trial to evaluate the safety and effectiveness of MGL-3196 (resmetirom) in patients with Non-Alcoholic Steatohepatitis (NASH) and… Ended

2024-510626-89-00 Non-Alcoholic Steatohepatitis (NASH) 5 2019-11-18
A Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis Ended

2023-506994-36-00 Ulcerative Colitis 5 2018-10-11
A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease Ended

2023-504736-18-00 Moderately to Severely Active Crohn's Disease 10 2018-07-26
Effects of NNC0194-0499, cagrilintide, and semaglutide alone or in combinations on liver damage and alcohol use in people with alcohol-relat… Ended

2023-508170-28-00 alcohol-related liver disease 4 2024-08-07
A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants with Cirrhosis-ZEAL-UNLOCK Ended

2023-506893-11-00 Cirrhosis of the liver is a condition in which the live 4 2024-04-19
Efficacy and Safety of JNJ-77242113 in Participants with Moderately to Severely Active Ulcerative Colitis Ended

2023-504673-20-00 Ulcerative Colitis 4 2023-12-06
STUDY TO EVALUATE THE SAFETY AND EFFICACY OF BEMNIFOSBUVIR AND RUZASVIR IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION Ended

2023-504566-28-00 Chronic Hepatitis C Virus (HCV) Infection 4 2023-05-19
Menthacarin® in the treatment of functional gastrointestinal disorders Ended

2022-501800-92-00 functional gastrointestinal disorders 6 2023-05-15
Clinical study to show if Naronapride tablets are safe and efficient for treatment of delayed stomach emptying and to find the optimal dose. Ended

2023-510195-31-00 Idiopathic or Diabetic Gastroparesis 4 2023-01-03
Study Evaluating the Efficacy and Safety of Belapectin (GR-MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis Ended

2024-512619-28-00 Esophageal Varices in NASH Cirrhosis 10 2021-03-08
A randomized, phase 3 multicenter clinical trial to confirm the clinical efficacy and evaluate the safety of linaprazan glurate compared to … Ended

2025-522750-39-00 Erosive esophagitis (EE) due to gastroesophageal reflux 5